Trial Profile
A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Poly ICLC (Primary)
- Indications Colon cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Feb 2023 Status changed from recruiting to completed.
- 27 Jul 2021 Planned End Date changed from 1 Jan 2021 to 1 Dec 2022.
- 27 Jul 2021 Planned primary completion date changed from 1 Jan 2021 to 1 Dec 2022.